SCHOFIELD, Wis., Jan. 15, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc, (OTCBB: PMBS) announces that its over-the-counter, homeopathic migraine pain reliever formulation, LipiGesic® M, has received a Notice of Allowance for its patent application from the United States Patent and Trademark Office.

LipiGesic M's exclusive formulation of feverfew and ginger delivered in a sublingual (under-the-tongue), non-aqueous gel has been clinically studied for the treatment of acute migraine at three prominent headache centers across the United States and has been found to be highly effective, as published in the June 2011 issue of the top-tier medical journal, Headache: The Journal of Head and Face Pain.

LipiGesic M also has been recognized as an excellent first-line therapy in the treatment of acute migraine that is compatible with all other acute treatments by Dr. Roger Cady in the article "Advances in Drug Development for Acute Migraine" published in the December 2012 issue of Drugs, a medical journal evaluating drugs and drug therapies read by over 500,000 healthcare providers.

"Allowance of the patent along with results of our clinical trial and recommendations from leading headache specialists prove that LipiGesic M is a unique and highly effective treatment for migraine headache and associated symptoms," said Russell Mitchell, president and CEO of PuraMed BioScience.

"LipiGesic M does not require a prescription. The all-natural formulation outperforms the leading prescription medications while costing up to 75 percent less," said Mitchell. "LipiGesic M gives migraineurs a powerful tool in the fight against migraines without the debilitating side effects, drowsiness, or rebound headaches caused by other chemically based prescription and over-the-counter migraine medications."

Presently, a clinical study is underway using LipiGesic M for treatment of migraine in children and adolescents. Results are expected in 2013.

About PuraMed BioScience®, Inc.: PuraMed BioScience, Inc. engages in the research, development, and marketing of non-prescription medicinal and healthcare products. PuraMed has completed a double-blind placebo clinical trial for its leading product, LipiGesic®M, a sublingual acute treatment for the relief of migraine headaches.

LipiGesic®M has achieved national distribution in some of the largest chain drug stores in the United States. In addition to LipiGesic® M, PuraMed BioScience also has plans to launch LipiGesic® H, a remedy for tension-type headaches, as well as LipiGesic® PM, a remedy for insomnia and other sleep disorders.

Forward-Looking Statements: This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.